Table 1.
Demographical and clinical characteristics of COVID‐19 patients
| White | Hispanic | p | |
|---|---|---|---|
| Total | 3289 | 770 | |
| *Age in years, median (IQR) | 70 (58–79) | 51 (37–63) | <0.001 |
| Male (%) | 52.7 | 51.7 | 0.63 |
| *BMI, median (IQR) | 29.7 (25.4–35.4) | 30.5 (27.3–36) | 0.0003 |
| Co‐morbidities (%) | |||
| Hypertension | 77.5 | 46.9 | <0.001 |
| Congestive heart failure | 33.4 | 12.0 | <0.001 |
| Diabetes Mellitus | 44.1 | 40.6 | 0.08 |
| HbA1c >10 | 19.4 | 17.5 | 0.23 |
| COPD | 40.2 | 19.0 | <0.001 |
| ESRD | 2.8 | 5.8 | <0.001 |
| Cirrhosis | 12.9 | 9.7 | 0.015 |
| Cancer | 14.7 | 6.9 | <0.001 |
| Venous thromboembolism | 6.8 | 2.1 | <0.001 |
| Medications at home (%) | |||
| On anticoagulation | 14.1 | 2.9 | <0.001 |
| On Aspirin | 17.6 | 15.5 | 0.16 |
| On Plavix | 6.1 | 2.5 | <0.001 |
| On ACEI or ARB | 31.1 | 20.4 | <0.001 |
| On beta blockers | 32.8 | 13.9 | <0.001 |
| On statin | 32.9 | 19.1 | <0.001 |
| COVID‐19 medications (%) | |||
| Vitamin C | 81.5 | 78.6 | 0.06 |
| Vitamin D | 26.0 | 16.5 | <0.001 |
| Thiamine | 7.7 | 3.9 | <0.001 |
| Ivermectin | 4.6 | 3.3 | 0.10 |
| Zinc | 80.8 | 78.3 | 0.11 |
| Hydroxychloroquine | 3.4 | 12.7 | <0.001 |
| Tocilizumab | 4.8 | 10.6 | <0.001 |
| Steroids | 70.2 | 55.7 | <0.001 |
| Convalescent plasma | 25.9 | 24.6 | 0.41 |
| Remedesivir | 56.7 | 47.7 | <0.001 |
| Anticoagulation | 75.0 | 74.5 | 0.84 |
| SOFA score at admission | 1 (0–2) | 0 (0–1) | <0.001 |
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; ESRD, end stage renal disease; IQR, interquartile range.
*
Median (interquartile range), number of samples.